The LDN Protocol: Dr. Bernard Bihari's Discovery of Immune Modulation Through Low-Dose Naltrexone

The Low-Dose Naltrexone (LDN) Protocol represents a paradigm-shifting approach to treating a wide spectrum of conditions, including autoimmune disease, cancer, chronic pain, and HIV/AIDS, through the immunomodulatory effects of ultra-low doses of the opioid antagonist naltrexone. First developed by the late Dr. Bernard Bihari in the mid-1980s, the protocol emerged from clinical observation during the height of the AIDS epidemic and has since garnered a substantial body of peer-reviewed research supporting its mechanisms and efficacy. Unlike conventional pharmaceutical approaches that suppress immune function, LDN acts as a biological response modifier, harnessing the body's endogenous opioid system to restore immune balance and inhibit pathological cell proliferation. This essay explores the protocol's origins, its multiple well-characterized mechanisms of action including the opioid growth factor pathway, glial cell modulation, and toll-like receptor antagonism the clinical evidence across diverse conditions, practical implementation considerations, and the growing acceptance of LDN within integrative and conventional medical communities.

---

1. Introduction: The Physician Who Healed Through Blockade

Dr. Bernard Bihari was a board-certified neurologist and psychiatrist practicing internal medicine in New York City during the 1980s when he made an observation that would fundamentally alter the therapeutic landscape for immune-mediated diseases . Trained at Harvard Medical School and with decades of clinical experience, Bihari was treating heroin addicts with a newly available medication called naltrexone, an opioid receptor antagonist approved by the FDA in 1984 for the treatment of opioid addiction at the standard dose of 50 milligrams daily .

As the AIDS epidemic unfolded around him, Bihari watched helplessly as many of his patients began dying from the devastating immune deficiency. Driven by the urgency of the crisis, he began searching for any intervention that might slow the progression of the disease. He knew that endorphins, the body's naturally produced neurochemicals, possessed not only pain-relieving properties but also immunomodulatory effects. When he measured endorphin levels in his HIV patients, he discovered they were consistently sub-normal .

This finding led Bihari to a novel hypothesis: if he could safely increase endorphin production, he might be able to bolster his patients' compromised immune systems. He theorized that very low doses of naltrexone, taken at bedtime, would briefly block opioid receptors in the brain. This temporary blockade would create a perceived deficiency of endorphin activity, triggering a compensatory increase in the body's own endorphin production during the overnight hours. The result was a two to three hundred percent increase in circulating endorphin levels, with corresponding improvements in immune function .

The story of LDN is also indebted to the foundational research of Dr. Ian Zagon and Dr. Patricia McLaughlin at Penn State University's Hershey Medical Center, who had been studying the opioid growth factor pathway since 1980 and would later elucidate the molecular mechanisms underlying LDN's effects on cell proliferation . Bihari's clinical genius was in translating this basic science into a practical therapeutic protocol that has since helped countless patients worldwide.

2. The Foundational Philosophy: Immune Modulation Through Endogenous Opioid Augmentation

The LDN Protocol is built upon a sophisticated understanding of the bidirectional relationship between the nervous system and the immune system. At its core lies the recognition that endorphins, far from being merely the body's natural painkillers, serve as critical signaling molecules that regulate immune function, inflammation, and cell growth.

Conventional approaches to autoimmune disease rely heavily on immunosuppression using corticosteroids, methotrexate, or biologic agents that broadly dampen immune activity. While often effective at controlling symptoms, these approaches carry significant long-term risks including increased susceptibility to infection, malignancy, and metabolic disturbances. Moreover, they do not address the underlying dysregulation that characterizes autoimmune conditions.

LDN operates on an entirely different principle. Rather than suppressing immune function, it seeks to restore normal immune regulation by enhancing the body's own homeostatic mechanisms. The transient blockade of opioid receptors by low-dose naltrexone creates a brief period of perceived endorphin deficiency, which stimulates increased production of both endorphins and opioid receptors. This upregulation persists beyond the duration of the drug's receptor blockade, resulting in sustained enhancement of endorphin signaling .

The therapeutic window for this effect is narrow and specific. Standard-dose naltrexone at 50 milligrams produces complete and sustained opioid receptor blockade, which suppresses endorphin signaling and can actually worsen immune function. Ultra-low doses in the range of 1.5 to 4.5 milligrams, by contrast, produce only partial and transient blockade, sufficient to trigger compensatory upregulation without causing prolonged interference with normal opioid physiology . This hormetic principle a beneficial effect from low-dose exposure to an agent that is neutral or harmful at higher doses is central to understanding LDN's unique pharmacology.

3. Comprehensive Mechanisms of Action

The therapeutic effects of LDN arise from multiple distinct but complementary mechanisms that have been elucidated through decades of basic and clinical research.

The Opioid Growth Factor Opioid Growth Factor Receptor Axis

The most fundamental mechanism underlying LDN's effects on cell proliferation involves the opioid growth factor and its receptor. OGF, chemically identical to met-enkephalin, is an endogenous opioid peptide that functions as a potent negative regulator of cell growth. Its receptor, OGFr, is expressed on a wide variety of cell types including epithelial cells, fibroblasts, and cancer cells .

Research by Zagon, McLaughlin, and colleagues has demonstrated that the duration of opioid receptor blockade determines the cellular response to naltrexone. Continuous blockade with high-dose naltrexone simulates the absence of OGF signaling, leading to accelerated cell proliferation. Intermittent blockade with low-dose naltrexone, by contrast, upregulates both OGF and OGFr expression at the translational level, enhancing the growth-inhibitory tone of the OGF-OGFr axis .

In human ovarian, pancreatic, colorectal, and squamous cell carcinoma cell lines, short-term exposure to LDN increased OGF and OGFr expression and inhibited cell proliferation through mechanisms requiring the cyclin-dependent inhibitory kinases p16 and p21. Importantly, these effects occurred independently of cell death pathways such as necrosis or apoptosis, indicating that LDN acts primarily as a cytostatic rather than cytotoxic agent . Sequential administration of LDN followed by exogenous OGF produced even greater inhibitory effects than either agent alone, suggesting potential combination strategies for cancer therapy.

Glial Cell Modulation and Neuroinflammation

At standard doses, naltrexone's primary action is on neuronal opioid receptors. At low doses ranging from one to five milligrams, however, LDN exerts important effects on glial cells, particularly microglia, the resident immune cells of the central nervous system .

Microglia become activated in response to various stressors including infection, injury, and chronic pain, producing a cascade of pro-inflammatory cytokines including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. This neuroinflammatory response contributes to pain sensitization, tissue damage, and disease progression in numerous neurological and autoimmune conditions .

LDN acts as a glial modulator by inhibiting microglial activation through its antagonism of toll-like receptor 4 on the cell surface. This disruption of the inflammatory signaling cascade reduces the synthesis of pro-inflammatory cytokines and slows the activation of microglial cells, resulting in both analgesic and anti-inflammatory effects . This mechanism explains LDN's efficacy in conditions characterized by neuroinflammation, including fibromyalgia, complex regional pain syndrome, and multiple sclerosis.

Toll-Like Receptor Antagonism

Beyond its effects on glial cells, LDN directly antagonizes toll-like receptors 7, 8, and 9 on immune cells. These pattern recognition receptors normally detect pathogen-associated molecular patterns and initiate innate immune responses. Their chronic activation has been implicated in autoimmune disease pathogenesis .

By blocking these receptors, LDN suppresses the production of interleukin-6 and other pro-inflammatory cytokines, dampening the aberrant immune activation characteristic of autoimmune conditions. This mechanism appears particularly relevant to LDN's effects in Crohn's disease, rheumatoid arthritis, and other inflammatory disorders .

Endorphin-Mediated Immune Enhancement

The original mechanism identified by Dr. Bihari remains central to understanding LDN's broad therapeutic effects. By increasing circulating endorphin levels by two to three hundred percent, LDN enhances the activity of natural killer cells and T-helper lymphocytes, both critical components of effective immune surveillance against pathogens and cancer cells .

Cancer cell surfaces express receptors for endorphins, and the increased endorphin levels resulting from LDN therapy can bind directly to these receptors, triggering apoptotic cell death in malignant cells while sparing healthy tissues. This endorphin-mediated oncolytic effect may explain the tumor regressions and prolonged remissions observed in some cancer patients treated with LDN .

4. Clinical Evidence Across Conditions

The evidence base for LDN has expanded dramatically since Dr. Bihari's initial observations, encompassing dozens of clinical studies across a wide range of conditions.

HIV and AIDS

Dr. Bihari's foundational work in HIV patients established the therapeutic potential of LDN. In a small controlled study, patients receiving LDN had an eight percent death rate after one year, compared to a thirty-three percent death rate in the placebo group . While the advent of highly active antiretroviral therapy has transformed HIV management, these early results demonstrated LDN's ability to enhance immune function and slow disease progression.

Cancer

The application of LDN to oncology has generated considerable interest, though the evidence remains largely anecdotal and mechanistic. Dr. Bihari reported that cancer patients treated with LDN experienced tumor shrinkage and prolonged remission, which he attributed to increased endorphin levels binding to cancer cell receptors and triggering apoptosis .

A 2022 review in Expert Review of Anticancer Therapy examined three mechanisms through which LDN may influence cancer progression: antagonism of toll-like receptors 7 through 9 leading to interleukin-6 suppression, modulation of immune function, and direct inhibition of cancer cell signaling pathways including the priming of pro-apoptotic pathways . The authors noted increasing anecdotal reports of activity and called for clinical trials of LDN in cancer, particularly in combination with certain chemotherapy agents .

Prominent oncologists including Professor Angus Dalgleish of St. George's University of London have advocated for greater research into LDN's anticancer effects, noting its favorable safety profile and low cost. Dalgleish has reported using LDN in his own cancer patients and has called attention to the need for rigorous clinical trials .

Fibromyalgia

Fibromyalgia is one of the most studied conditions in the LDN literature, though results have been mixed. A 2025 systematic review and meta-analysis published in the Journal of Pain and Palliative Care Pharmacotherapy examined eight clinical trials comparing LDN to placebo in fibromyalgia patients .

Within the LDN treatment groups, pain scores decreased substantially from baseline with a standardized mean difference of 1.03, and fibromyalgia symptom severity decreased with a standardized mean difference of 1.02. However, when LDN was compared directly to placebo, no significant differences were observed for either pain reduction or symptom severity improvement. The authors concluded that while LDN marginally reduced pain and symptom severity from baseline, these effects were not superior to placebo, suggesting that LDN may not provide significant clinical benefit over placebo in fibromyalgia management .

These findings highlight the importance of placebo-controlled trials in conditions with high placebo response rates and suggest that the perceived benefits of LDN in fibromyalgia may be partly attributable to nonspecific effects. Further research with larger sample sizes and standardized dosing protocols is needed.

Multiple Sclerosis

Multiple sclerosis is another condition for which LDN has shown promise. By modulating microglial activation and reducing neuroinflammation, LDN may slow disease progression and alleviate symptoms. Several small studies and numerous patient reports have described improvements in quality of life, spasticity, and pain, though large randomized controlled trials remain limited .

Complex Regional Pain Syndrome

CRPS, a severe neuropathic pain condition characterized by glial cell activation and central sensitization, has been successfully treated with LDN in published case reports. Two patients with refractory CRPS who had failed conventional pharmacotherapy including anticonvulsants, antidepressants, and opioids experienced dramatic improvements after starting LDN .

One patient who developed widespread CRPS symptoms following cardiac bypass surgery had dystonic spasms requiring intravenous ketamine infusions. Within two months of starting LDN, their dystonic spasms resolved completely, they were able to walk without a cane, their pain level dropped three to four points on the Numeric Rating Scale, and pain severity reduced significantly. Both patients experienced no side effects from LDN .

Autoimmune and Inflammatory Conditions

LDN has been studied in numerous other autoimmune and inflammatory conditions including Crohn's disease, Hashimoto's thyroiditis, rheumatoid arthritis, and systemic lupus erythematosus. A 2025 scoping review of LDN's therapeutic uses identified sixty-eight articles presenting clinical examples of efficacy for a variety of medical conditions, though the authors noted significant gaps in research and called for larger clinical trials and proper dosing studies .

Dermatologic applications have also been explored, with LDN showing particular promise in Hailey-Hailey disease, a rare blistering disorder, as well as in psoriasis and other inflammatory skin conditions .

5. The Protocol in Practice: Dosing and Administration

The clinical application of LDN requires careful attention to dosing, timing, and patient selection based on principles established by Dr. Bihari and refined through decades of clinical experience.

Dosing Range

The therapeutic dose range for LDN is typically 1.5 to 4.5 milligrams taken once daily at bedtime. This contrasts sharply with the standard 50 milligram dose used for addiction treatment and represents a fundamental difference in therapeutic intent .

Treatment is usually initiated at the lower end of the dosing range, typically 1.5 milligrams, and gradually increased over several weeks to the optimal maintenance dose. Some patients may respond best to doses as low as 0.5 milligrams, while others may require up to 6 milligrams, though the 4.5 milligram dose is most commonly cited as the therapeutic target .

Timing and Administration

The timing of LDN administration is critical to its mechanism of action. Patients are instructed to take their dose immediately before bedtime, typically between 9 PM and midnight. This timing ensures that the transient opioid receptor blockade occurs during the overnight hours when endorphin production is normally at its peak. The compensatory upregulation of endorphin synthesis then occurs during sleep, with elevated endorphin levels persisting throughout the following day .

LDN is usually formulated as a capsule or liquid for accurate dosing, as the 4.5 milligram dose is not commercially available as a standard manufactured product. Compounding pharmacies prepare LDN from bulk naltrexone powder, ensuring precise dosing and appropriate excipients.

Duration of Treatment

The time course of response to LDN varies considerably depending on the condition being treated and individual patient factors. Some patients, particularly those with pain conditions, may notice improvement within days to weeks. Others, including many cancer and autoimmune patients, may require two to three months of continuous treatment before experiencing maximal benefit .

Once a therapeutic response is achieved, LDN therapy is typically continued indefinitely to maintain disease control. There is no evidence of tolerance developing to LDN's effects, and many patients have remained on stable doses for years without loss of efficacy.

6. Safety Considerations and Contraindications

LDN is notable for its favorable safety profile, particularly when compared to the immunosuppressive medications it often replaces. However, several important safety considerations must be addressed.

Common Side Effects

Most side effects of LDN are mild and transient, typically resolving within the first few weeks of treatment. The most commonly reported effects include vivid dreams or sleep disturbances, which occur in a minority of patients and often subside with continued use or dose adjustment. Headache, dizziness, gastrointestinal symptoms such as nausea or diarrhea, and mild anxiety have also been reported .

These side effects are generally dose-dependent and can often be managed by temporarily reducing the dose and titrating more slowly. Taking the medication at bedtime helps many patients tolerate any initial sleep-related effects.

Serious Adverse Effects

Serious adverse effects from LDN are rare but do occur. Hepatotoxicity has been reported with naltrexone, particularly at higher doses, though this appears uncommon at LDN doses. Patients with pre-existing liver disease should have baseline liver function testing and periodic monitoring while on therapy .

Severe allergic reactions including rash, urticaria, and angioedema may occur in susceptible individuals. Patients should be instructed to seek medical attention if they develop signs of a hypersensitivity reaction.

Contraindications

Several absolute and relative contraindications to LDN must be respected:

Current Opioid Use: The most critical contraindication is the presence of opioids in the patient's system. Naltrexone will precipitate acute opioid withdrawal in any patient who has used opioids within the preceding seven to ten days. This withdrawal can be severe and requires immediate medical attention. Patients must be completely opioid-free before initiating LDN .

Severe Liver Disease: Patients with acute hepatitis, hepatic failure, or severe liver impairment should not receive naltrexone due to the risk of hepatotoxicity and impaired drug metabolism .

Pregnancy and Breastfeeding: The safety of naltrexone during pregnancy and lactation has not been established. LDN should only be used in pregnant or breastfeeding women when the potential benefits clearly outweigh the risks, and only under close medical supervision .

Drug Interactions

Several important drug interactions must be considered when prescribing LDN:

Opioid-Containing Medications: Any medication containing opioids, including prescription pain relievers such as codeine, hydrocodone, morphine, and oxycodone, as well as over-the-counter products containing opioid derivatives such as some cough suppressants and antidiarrheals, will be blocked by naltrexone and may precipitate withdrawal .

Benzodiazepines: Concurrent use of benzodiazepines with naltrexone may increase the risk of adverse effects and should be approached with caution. Some patients may require ongoing benzodiazepine therapy under close monitoring .

Liver Enzyme Interactions: Medications that affect liver enzyme function may alter naltrexone metabolism, though clinically significant interactions are uncommon at LDN doses.

7. Monitoring and Follow-Up

Appropriate monitoring ensures safe and effective LDN therapy. Baseline assessment should include liver function tests, particularly in patients with known liver disease or risk factors. Patients with autoimmune conditions may benefit from baseline disease activity markers against which to measure response .

During the initial titration phase, patients should be seen or contacted frequently to assess tolerance and adjust dosing. Once a stable maintenance dose is achieved, follow-up at three to six month intervals is typically sufficient for most patients.

Monitoring parameters should include:

· Liver function tests at baseline and periodically thereafter

· Assessment of disease-specific markers where applicable

· Symptom scores and quality of life measures

· Adverse effect monitoring

· Assessment of ongoing opioid use

Patients should be educated about the importance of reporting any new medications to their prescribing physician, as inadvertent opioid exposure could precipitate withdrawal.

8. The State of Evidence and Future Directions

The evidence base for LDN has matured considerably since Dr. Bihari's pioneering work, yet significant gaps remain. The 2025 scoping review by Leiber and colleagues identified sixty-eight clinical studies examining LDN's efficacy across numerous conditions, but the authors emphasized the need for larger randomized controlled trials and proper dosing studies .

The mixed results in fibromyalgia highlight the importance of rigorous trial design in conditions with high placebo response rates. While LDN consistently produces improvements from baseline, demonstrating superiority to placebo has proven more challenging. Future studies must employ adequate sample sizes, standardized dosing protocols, and validated outcome measures to definitively establish LDN's role in specific conditions .

The application of LDN to oncology represents perhaps the most exciting frontier. The mechanistic evidence from cell culture studies demonstrating inhibition of cancer cell proliferation through the OGF-OGFr pathway provides a strong rationale for clinical investigation . The anecdotal reports of tumor regression, combined with LDN's favorable safety profile and low cost, support the urgent need for formal clinical trials in cancer patients .

Combination strategies also warrant investigation. The demonstration that sequential administration of LDN and exogenous OGF produces greater inhibitory effects than either agent alone suggests potential synergies with conventional chemotherapy that could enhance efficacy while reducing toxicity . Clinical trials examining LDN in combination with standard anticancer agents are needed to explore these possibilities.

Professor Dalgleish and other advocates have called for greater recognition of LDN within mainstream oncology, noting that the drug's low cost and lack of patent protection create disincentives for pharmaceutical industry investment in clinical trials . Public funding and philanthropic support will likely be necessary to advance LDN research to the level required for regulatory approval in cancer and other off-label indications.

9. Conclusion

The LDN Protocol developed by Dr. Bernard Bihari represents one of the most important repurposed drug discoveries of the modern era. Arising from clinical observation during the AIDS crisis and grounded in decades of basic science research on opioid growth factor biology, LDN offers a safe, inexpensive, and mechanistically sound approach to immune modulation that stands in stark contrast to conventional immunosuppressive strategies.

The multiple mechanisms through which LDN exerts its therapeutic effects including OGF-OGFr upregulation, glial cell modulation, toll-like receptor antagonism, and endorphin-mediated immune enhancement provide a rational basis for its application across a remarkably diverse range of conditions. From autoimmune disease and chronic pain to cancer and HIV, LDN targets fundamental pathways of immune dysregulation and pathological cell proliferation.

The clinical evidence, while still evolving, supports LDN's use in numerous conditions. The dramatic responses observed in refractory CRPS patients, the improved outcomes in HIV, the tumor regressions reported in cancer, and the symptom relief experienced by countless patients with autoimmune diseases attest to LDN's therapeutic potential. The mixed results in fibromyalgia serve as a reminder that not all conditions respond equally and that rigorous research remains essential.

Several important considerations distinguish LDN from conventional pharmaceutical approaches. The narrow therapeutic window requires careful dosing and individualization. The timing of administration relative to sleep is critical for optimal effect. The contraindications particularly current opioid use must be strictly observed to avoid precipitated withdrawal. The favorable safety profile, however, makes LDN an attractive option for patients who have failed or cannot tolerate standard therapies.

The future of LDN depends on continued research investment and clinical innovation. Large randomized controlled trials are needed to establish efficacy definitively in specific conditions. Mechanistic studies should continue to elucidate LDN's effects at the molecular level. Combination strategies with conventional therapies warrant exploration. Most importantly, the legacy of Dr. Bihari's compassionate and intellectually rigorous approach to patient care must be honored through continued commitment to understanding and applying this remarkable therapy.

For patients with conditions lacking effective treatments, for those who cannot tolerate immunosuppressive medications, and for those seeking safer alternatives to chronic opioid therapy, LDN offers hope grounded in sound science and decades of clinical experience. As Professor Dalgleish has emphasized, the story of LDN demonstrates that important therapeutic advances can emerge from repurposing old drugs when physicians remain open to unexpected observations and committed to serving their patients' needs . In an era of escalating healthcare costs and widespread opioid harm, LDN stands as a testament to the enduring value of clinical wisdom, scientific rigor, and therapeutic parsimony.

10. Key Published Works and Resources

Foundational Publications: Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Experimental Biology and Medicine. 2011;236(9):1036-1050 .

Cancer Review: Liu WM, Dalgleish AG. Naltrexone at low doses (LDN) and its relevance to cancer therapy. Expert Review of Anticancer Therapy. 2022;22(3):269-274 .

Fibromyalgia Meta-Analysis: Ologunowa A, et al. Efficacy of low-dose naltrexone in treating patients with fibromyalgia: systematic review and meta-analysis. Journal of Pain and Palliative Care Pharmacotherapy. 2025; Online ahead of print .

Scoping Review: Leiber KK, et al. Therapeutic uses and efficacy of low-dose naltrexone: a scoping review. Cureus. 2025;17(3):e81086 .

Historical and Clinical Overview: Lynch K. Low-dose naltrexone: treating pain and more. American Academy of Anti-Aging Medicine. 2021 .

Clinical Resource: The LDN Research Trust (ldnresearchtrust.org) provides comprehensive information for patients and practitioners .

Case Reports: Chopra P, Cooper MS. Treatment of complex regional pain syndrome with low-dose naltrexone. Pain Medicine. 2013;14(2):318-320 [cited in citation:2].